Guardant Health stock has delivered an exceptionally strong 3 year return, yet its valuation checks are pulling in different directions, with a Discounted Cash Flow (DCF) intrinsic value estimate suggesting the shares trade below intrinsic value while market based multiples point to an expensive profile.

• Over the past 3 years Guardant Health has returned 313.6%, which puts added focus on whether the current price still aligns with the underlying cash flow outlook.
• Expanded coverage for the Shield colorectal cancer test and broader test adoption can support higher long term revenue expectations, while ongoing cash burn and recent insider share sales may weigh on how much investors are willing to pay for that growth.
• Guardant Health scores 1 out of 6 on the broader valuation checks, which leans more toward an expensive stock than a clear bargain.

The stock's next move may depend on whether investors ultimately side with the intrinsic value estimate that indicates Guardant Health is 16.1% below that DCF based fair value, or with the richer market multiples that suggest the shares already price in a lot of optimism.

Is Guardant Health a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Guardant Health could be worth based on its projected cash flows. For Guardant Health, the latest twelve month free cash flow is a loss of $232.5 million, so the model assumes cash flows recover over time rather than stay at current levels.

On those projections, the DCF points to an intrinsic value of about $186 per share, which is roughly 16.1% above the current share price, so the stock appears undervalued on this method. Because UnitedHealth is set to expand coverage for Guardant Health’s Shield colorectal cancer test, the market may be giving more credit to long term cash flow potential than recent cash burn alone would suggest.

On this DCF view, Guardant Health stock currently appears undervalued relative to its projected cash generation.

Our Discounted Cash Flow (DCF) analysis suggests Guardant Health is undervalued by 16.1%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Has Guardant Health Run Too Far on Sales?

P/S is often a useful lens for Guardant Health because the company is still reporting accounting losses, so earnings based ratios are less informative than revenue based ones.

Guardant Health currently trades on a P/S ratio of about 19.2x, compared with a Healthcare industry average of roughly 1.5x and a peer average near 1.5x. On Simply Wall St’s tailored fair ratio, which adjusts for the company’s growth profile, margins, size and risk, Guardant Health screens at about 8.4x P/S, so the current multiple sits well above that benchmark.

This gap indicates that investors are paying a substantial premium for each dollar of Guardant Health’s sales, even after factoring in its characteristics and sector. While recent enthusiasm around expanded Shield test coverage helps explain strong interest in the stock, the P/S ratio suggests expectations embedded in the price are already very high.

On the P/S multiple, Guardant Health stock appears expensive relative to both sector norms and its own fair ratio benchmark.

The Guardant Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Guardant Health pick up where this valuation split leaves off. They spell out the growth, margin and earnings paths that would need to play out for the stock to be worth materially more or less than today’s price. Each narrative ties a fair value estimate to a specific mix of potential catalysts and risks for Guardant Health, so you can track over time which version of the story is actually developing.

One of the top community narratives on Guardant Health: 90% overvalued

"Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high..."

Do you think there's more to the story for Guardant Health? Head over to our Community to see what others are saying!

The Bottom Line

For Guardant Health, the Discounted Cash Flow (DCF) intrinsic value points to the stock trading at a discount, while the market multiple view flags it as overvalued. That split largely reflects how the DCF leans on long term cash flow recovery, whereas the richer P/S ratio leans on strong sentiment and high growth expectations. With the broader valuation checks still weak, the key question is whether future revenue growth and cash generation will justify today’s premium sales multiple or whether that optimism proves too generous.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.